| 11/03/2026 12:30 |
Conferment of the Purple Ribbon Medal of Honor upon Kazuhiko NAKATANI, Senior Research Fellow of Veritas In Silico |
| 11/02/2026 17:20 |
Monthly Status of Exercise of #5 (with Exercise Price Adjustment Clause) and #6 to #9 Share Acquisition Rights(with Target Issue and Adjustment Optio |
| 11/02/2026 15:30 |
Syntara and Veritas In Silico sign MoU to Accelerate Joint Discovery Research for mRNA-Targeted Compounds |
| 10/29/2026 13:00 |
Notice of Completion of Payment for #5 and #6 to #9 Share Acquisition Rights by Third-Party Allotment |
| 10/19/2026 17:00 |
Notice Concerning Achievement of Research Milestone under Joint Drug Discovery with Toray Industries, Inc. |
| 08/05/2026 15:30 |
Financial Briefing Materials - FY2026 Second Quarter |
| 08/05/2026 15:30 |
Non-consolidated Financial Results for the Six Months Ended June 30, 2026 [Under Japanese GAAP] |
| 08/03/2026 12:00 |
Joint Patent Application Filed for lncRNA-Targeting Drugs |
| 07/13/2026 15:30 |
Personnel Changes in Executive Officer |
| 05/18/2026 12:30 |
Pre-Consultation Meeting with Pharmaceuticals and Medical Devices Agency (PMDA) towards the Commercialization of the Drug Delivery System "Perfusio" |
| 05/11/2026 15:30 |
Financial Results - FY2026 First Quarter |
| 05/11/2026 15:30 |
SpiroChem and Veritas In Silico entered into Joint Research Agreement to Initiate the Discovery of Next Generation mRNA Binding Chemical Matter |
| 05/11/2026 15:30 |
Notice of Extraordinary Loss Due to Impairment Accounting |
| 05/11/2026 15:30 |
Non-consolidated Financial Results for the Three Months Ended March 31,2026 [Under Japanese GAAP] |
| 04/27/2026 17:00 |
Announcement of the Publication of a Research Article on AISLAR, a Method for Streamlining Screening That Supports Our AI-Driven Drug Discovery |
| 04/13/2026 15:30 |
Termination of Collaborative Drug Discovery Research with Takeda on mRNA-Targeted Small-Molecule Drugs |
| 02/19/2026 18:00 |
Appointing Candidates for Directors, Auditor, and Alternate Audit & Supervisory Board Member |
| 02/12/2026 12:00 |
Financial Results - Fiscal Year Ended December 31, 2025 |
| 02/12/2026 12:00 |
Company Presentation |
| 02/12/2026 12:00 |
Summary of Non-consolidated Financial Results for the Fiscal Year ended December 31, 2025 [Under Japanese GAAP] |
| 01/26/2026 17:00 |
SpiroChem and Veritas In Silico Sign MoU to Accelerate Discovery of Next Generation RNA Binding Chemical Matter |
| 01/19/2026 13:30 |
The Jikei University School of Medicine and Veritas In Silico announce Patent Publication for Novel Nucleic Acid Therapeutic Targeting ALS |
| 01/05/2026 08:00 |
Upgrading the Drug Discovery Platform ibVIS to aibVIS |
| 12/22/2025 15:30 |
Patent Application for the mRNA-Targeted Nucleic Acid Drugs in the In-house Pipeline |
| 12/15/2025 17:00 |
Completion of Patent Examination and Patent Grant Procedures for Drug Delivery System "Perfusio" |
| 12/15/2025 17:00 |
Company Presentation |
| 11/17/2025 15:30 |
Start of Joint Research Project with Shimane University Aimed at Developing a Novel Drugs to Suppress Post-Lung Transplant Dysfunction |
| 11/11/2025 16:00 |
Organizational Reforms and Personnel Changes |
| 11/11/2025 16:00 |
[Summary] Financial Results for the Nine Months |
| 11/11/2025 16:00 |
Non-consolidated Financial Results for the Nine Months Ended September 30, 2025 [Under Japanese GAAP] |
| 11/04/2025 15:30 |
Dexerials Corporation and Veritas In Silico announce Start of Joint Technology Development for Establishing High-Speed and High-Accurate Spectroscopic |
